From the Director

Welcome to our second Tufts CSDD Quarterly Update of 2014. As we reach the midpoint of the calendar year, we at CSDD find that it's a good time to look back at what we've accomplished to date, and recalibrate our efforts as necessary to ensure that we meet our research and programming goals for the year. It's certainly been a productive and fulfilling first six months, and I'm excited about what's in store for the second half of 2014.

On a personal note, on May 30th I had the privilege of participating in a Healthcare Innovation Panel, hosted by Bill Gates and held at the Bill and Melinda Gates Foundation in Seattle. Thought leaders from academia, the drug and device industries, venture capital, and foundations engaged in a stimulating and far-reaching discussion of how to boost cutting-edge AND cost-cutting innovation to treat broad indications, such as cardiovascular disease, type 2 diabetes, and Alzheimer's disease, which are putting an unsustainable strain on global healthcare systems. Bringing the best minds together to address these issues is a critical step forward.

This quarter we say goodbye to research analysts Abbie Felix, Jessie Moskowitz, and Paulami Naik, who are leaving to pursue new career opportunities. We thank them for their hard work and dedication to CSDD and wish them success in all their endeavors. Despite their departure, our research efforts have not slowed a bit, as we have a stellar group of new interns and research analysts who have joined an outstanding core of research support staff at the Center.

As always, feel free to contact me directly to share your thoughts and perspectives. And thank you for your support. 

Research Opportunities    

Sponsored Research 

• Challenges Facing Biosimilar Uptake
• Impact of Reimbursement on Innovation
• Mapping Product-Specific Adverse Event Reporting in Institutional and Ambulatory Settings
• Mapping the US Generic Manufacturing Landscape
• Personalized Medicine Landscape
• Profiling Cycle Time and Cost of Vaccine Development
• Profiling New R&D Innovations Driving Performance and Efficiency
• Quantifying the Use of ePRO in Clinical Trials 

DiMasi JA, Milne C-P, Tabarrok A. An FDA report card: wide variance in performance found among agency's drug review divisions. Project FDA Report. No. 7, April 2014;  Manhattan Institute for Policy Research.

Lamberti MJ, Getz KA, Naik P, Costello M. Clinical supply capabilities, practices, and perceptions among investigative sites. Applied Clinical Trials Online 2014. [Published online before print May 12, 2014]

Milne C-P, Garafalo S, Bryan C, McKiernan M. Trial watch: Personalized medicines in late-stage development. Nature Reviews Drug Discovery. 2014;13(5):324-325.

Smed M, Getz KA. Site characteristics influencing the translation of clinical research into clinical practice. Therapeutic Innovation & Regulatory Science 

For more information on publications from Tufts CSDD's faculty staff, please contact our Information Services Librarian Sandra Peters.

JUNE

Mary Jo Lamberti: Barnett Clinical Trial Oversight Summit, Boston, MA, June 2-5

Christopher-Paul Milne: American Conference Institute (ACI), 5th Annual Summit on Biosimilars, New York, NY, June 4-5 

Kenneth Getz: Pharmaceutical Executive Conference, New York, NY, June 12

Joseph DiMasi, Kenneth Getz, Kenneth Kaitin, Mary Jo Lamberti, Stella Stergiopoulos: Drug Information Association Annual Meeting, San Diego, CA, June 16 -19

JULY

Joseph DiMasi: World Transplant Congress, San Francisco, CA, July 26-31